Appendix 1: Screening, inclusion, exclusion process

**Montreal Chest Institute**

**Screening criteria**
Documented diagnosis of NHL according to clinical database between 01Jan2002 and 01Jan2010

N = 29

**Reasons for exclusion:**
- No documented DLBCL: 8 (Burkitt’s: 2)
- Prior chemotherapy: 6
- No cART: 1
- Did not receive CHOP: 2 (Received mCHOP: 1)
- Not within time period: 1
- Lack of information: 2

** Included patients**
N = 9

**Centre Hospitalier de l’Université de Montréal**

**Screening criteria**
Prior diagnosis of AIDS/HIV and documented DLBCL between 01Jan2002 and 01Jan2010 according to archive’s diagnosis coding system

N = 39

**Reasons for exclusion:**
- No documented DLBCL: 8 (Burkitt’s: 2; Plasmablastic: 1)
- Prior chemotherapy: 2
- No cART: 4
- Did not receive CHOP: 11 (Received mCHOP: 4)
- Not within time period: 2

**Included patients**
N = 12

**Princess Margaret Hospital**

**Screening criteria**
Patients who received CHOP identified through the pharmacy dispensing system between 01Jan2002 and 01Jan2010

N = 748

**Reasons for exclusion:**
- Not HIV positive or no documented DLBCL: 720
- Prior chemotherapy: 2
- No cART: 7; Unknown cART: 1
- Did not receive CHOP: 4 (Received mCHOP: 4)
- Not within time period: 1

**Included patients**
N = 13

---

a: one patient received CHOP every 14 days and not every 21 days.
b: one patient transferred from another centre, one patient chart not accessible
c: two patients had empiric vincristine dose reduction; two patients had doxorubicin omitted in first chemotherapy cycle
d: due to the number of patients screened, HIV diagnosis and documented DLBCL were screened simultaneously. The vast majority of patients screened were HIV negative however.
e: four patients did not receive full dose of CHOP

Abbreviations: cART (combination antiretroviral therapy), CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), DLBCL (diffuse large B cell lymphoma), mCHOP (modified CHOP chemotherapy), NHL (non Hodgkin’s lymphoma),
Appendix 2: Rate of grade 3 and 4 adverse events according to the total number of chemotherapy cycles

<table>
<thead>
<tr>
<th></th>
<th>All, n (%)&lt;sup&gt;b&lt;/sup&gt;</th>
<th>PI, n (%)&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Non-PI, n (%)&lt;sup&gt;b&lt;/sup&gt;</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of cycles</td>
<td>201</td>
<td>133</td>
<td>68</td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>55 (27)</td>
<td>30 (23)</td>
<td>25 (37)</td>
<td>0.04</td>
</tr>
<tr>
<td>Acute kidney injury</td>
<td>2 (1)</td>
<td>1 (1)</td>
<td>1 (1)</td>
<td>1.00</td>
</tr>
<tr>
<td>ALT/AST</td>
<td>7 (4)</td>
<td>4 (3)</td>
<td>3 (4)</td>
<td>0.69</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>5 (3)</td>
<td>4 (3)</td>
<td>1 (1)</td>
<td>0.66</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>22 (11)</td>
<td>17 (13)</td>
<td>5 (7)</td>
<td>0.34</td>
</tr>
<tr>
<td>Non-infective cystitis or hematuria</td>
<td>1 (0.5)</td>
<td>0 (0)</td>
<td>1 (1)</td>
<td>0.34</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1 (0.5)</td>
<td>0 (0)</td>
<td>1 (2)</td>
<td>0.34</td>
</tr>
<tr>
<td>Emergency visit&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6 (3)</td>
<td>2 (2)</td>
<td>4 (6)</td>
<td>0.18</td>
</tr>
<tr>
<td>Infection</td>
<td>9 (4)</td>
<td>7 (5)</td>
<td>2 (3)</td>
<td>0.72</td>
</tr>
<tr>
<td>Any adverse event</td>
<td>88 (44)</td>
<td>57 (43)</td>
<td>31 (46)</td>
<td>0.77</td>
</tr>
</tbody>
</table>

<sup>a</sup> Not graded according to the Common Terminology Criteria for Adverse Events

<sup>b</sup> Percentages calculated according to the total number of chemotherapy cycles given in each group.

Abbreviations: ALT (alanine transaminase), AST (aspartate transaminase), non-PI (non-protease inhibitor based combination antiretroviral therapy), PI (protease inhibitor based combination antiretroviral therapy)